Malnutrition, cardiac disease, and mortality

Peritoneal Dialysis International

Volumn 19, Issue SUPPL. 2, 1999, Pages

  Bergström, Jonas ^a   Lindholm, Bengt ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cardiac disease; Hypoalbuminemia; Inflammation; Malnutrition; Mortality

Indexed keywords

ACUTE PHASE PROTEIN; ALBUMIN; AMINO ACID; CYTOKINE; LIPOPROTEIN A;

ALBUMIN BLOOD LEVEL; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DIABETES MELLITUS; HUMAN; HYPOALBUMINEMIA; KIDNEY FAILURE; LIPOPROTEIN BLOOD LEVEL; MORTALITY; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROTEIN CALORIE MALNUTRITION; RISK FACTOR;

EID: 0033401425     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686089901902s52     Document Type: Conference Paper

References (66)

1. United States Department of Health and Human Services, Public Health Service, National Institutes of Health. USRDS 1997 Annual Data Report. Bethesda: United States Renal Data System; 1997.
2. Silberberg JS, Barré PE, Prichard SS, Sniderman AD. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int. 1989; 36:286-90.
3. Bergström J. Nutrition and mortality in hemodialysis. J Am Soc Nephrol. 1995; 6:1329-41.
4. Lowrie EG, Lew NL. Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis. 1990; 15:458-82.
5. Maiorca R, Cancarini GC, Brunori G, Camerini C, Manili L. Morbidity and mortality of CAPD and hemodialysis. Kidney Int. 1993; 42(Suppl 40):S4-15.
6. Kaysen GA, Rathore V, Shearer GE, Depner TA. Mechanisms of hypoalbuminemia in hemodialysis patients. Kidney Int. 1995; 48:510-16.
7. Struijk DG, Krediet RT, Koomen GCM, Boeschoten EW, Arisz L. The effect of serum albumin at the start of continuous ambulatory peritoneal dialysis treatment on patient survival. Perit Dial Int. 1994; 14:121-30.
8. European Dialysis Transplant Association/European Renal Association Registry Report. Demography of dialysis and transplantation in Europe 1984. Nephrol Dial Transplant. 1986; 1:1-8.
9. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barré PE. Hypoalbuminemia, cardiac morbidity, and mortality in end-stage renal disease. J Am Soc Nephrol. 1996; 7:728-36.
10. Qureshi AR, Anderstam B, Danielsson A, Divino-Filho JC, Gutierrez A, Lindholm B, et al. Factors predicting malnutrition in hemodialysis patients. Kidney Int. 1998; 53:773-82.
11. Stenvinkel P, Heimbürger O, Tuck C, Berglund L. Apo(a)-isoform size and nutritional status in patients with chronic renal failure. Kidney Int. 1998; 53:1336-42.
12. Warton BA, Palmer SE, Somers K. The myocardium in kwashiorkor. Q J Med. 1969; 38:107-16.
13. Sjöström M, Wretlind ML, Karlberg I, Eden E, Lundholm K. Ultrastructural changes and enzyme activities for energy production in hearts concomitant with tumor-associated malnutrition. J Surg Res. 1987; 42:304-13.
14. Anker SD, Ponikowski P, Varney S, Chua TP, Clark AL, Well-Peploe KM, et al. Wasting as independent risk factor for mortality in heart failure. Lancet. 1997; 349:1050-3.
15. Cianflone K, Vu H, Zhang Z, Sniderman AD. Effect of albumin on lipid synthesis, apoB100 secretion, and LDL catabolism in human HepG2 cells. Atherosclerosis. 1994; 107:125-35.
16. Cianflone K, Zhang Z, Vu V, Kohen-Aramogul R, Kalant D, Sniderman AD. The effect of individual amino acids on apoB100 and Lp(a) secretion by HepG2 cells. J Biol Chem. 1996; 271:29136-45.
17. Kario K, Matsuo T, Kobyasahi H. Heparin cofactor II deficiency in the elderly: Comparison with antithrombin II. Thromb Res. 1992; 66:489-98.
18. Joles JA, Willekes-Koolschij N, Koomans HA. Hypoalbuminemia causes high blood pressure by increasing red cell lysophosphatidylcholine. Kidney Int. 1997; 52:761-70.
19. Löwe GDO, Drummond MM, Lorimer AR, Hutton I, Forbes DC , Prentice CRM, et al. Relation between extent of coronary arterial disease and blood viscosity. Br Med J. 1980; 280:673-4.
20. Blackburn GL, Gibbon GW, Bothe A, Benotti PN, Harken H, McEnary TM. Nutritional support in cardiac cachexia. J Thorac Cardiovasc Surg. 1977; 73: 4889-96.
21. Carr JG, Stevenson LW, Walden JA, Heber D. Prevalence and hemodynamic consequences of malnutrition in severe congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1989; 63:709-13.
22. Freeman LM, Roubenoff R. The nutrition implications of cardiac cachexia. Nutr Rev. 1994; 52:340-7.
23. Riley M, Elborn JS, McKane WR, Bell N, Stanford CS, Nicholls DP. Resting energy expenditure in chronic cardiac failure. Clin Sci. 1991; 80:633-9.
24. Poehlman ET, Scheffers J, Gottlieb SS, Fischer ML, Vaitekevicius P. Increased resting metabolic rate in patients with congestive heart failure. Ann Intern Med. 1994; 121:860-2.
25. Pittman JG, Cohen P. The pathogenesis of cardiac cachexia. N Engl J Med. 1964; 271:403-9.
26. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990; 323:236-41.
27. Munger MA, Johnson B, Amber IJ, Callahan KS, Gilbert EM. Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1996; 77:723-7.
28. Steele IC, Nugent A-M, Maguire S, Hoper M, Campgell G, Halliday MI, et al. Cytokine profile in chronic heart failure. Eur J Clin Invest. 1996; 26:1018-22.
29. Hosenpud JD, Campbell SM, Mendelson DJ. Interleukin-1-induced myocardial depression in an isolated beating heart preparation. J Heart Transplant. 1989; 8:460-4.
30. Yokoyama T, Vaca L, Rossen RD, Durante W, Hazarika P, Mann DL. Cellular effects of tumor necrosis factor-a in the adult mammalian heart. J Clin Invest. 1993; 92:2302-12.
31. Bistrian BR, Schwartz J, Istifan NW. Cytokines, muscle proteolysis and the catabolic response to infection and inflammation. Proc Soc Exp Biol Med. 1992; 200:220-3.
32. Roubenoff R, Roubenoff RA, Cannon JG, Kehayias JJ, Zhuang H, Dawson-Hughes B, et al. Rheumatoid cachexia: cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation. J Clin Invest. 1994; 93:2379-86.
33. Weingarten HP. Cytokines and food intake: The relevance of the immune system to the study of ingestive behavior. Neurosci Biobehav Rev. 1996; 20:163-70.
34. Ramadori G, VanDamme J, Rieder H, Meyer K-H. Interleukin 6, the third mediator of acute-phase reaction, modulates hepatic protein synthesis in human and mouse. Eur J Immunol. 1988; 18:12544-64.
35. Doweiko JP, Nompleggi DJ. The role of albumin in human physiology and pathophysiology. Part III: Albumin and disease states. JPEN J Parenter Enteral Nutr. 1991; 15:476-82.
36. Bárány P, Divino-Filho JC, Bergström J. High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am J Kidney Dis. 1997; 29:565-8.
37. Kaysen GA, Stevenson FT, Depner TA. Determinants of albumin concentration in hemodialysis patients. Am J Kidney Dis. 1997; 29:658-68.
38. Alexander RW. Inflammation and coronary heart disease. N Engl J Med. 1994; 331:468-9.
39. Heinrich J, Schulte H, Schonfeld R, Kohler R, Assman G. Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain. Thromb Haemost. 1995; 73:373-9.
40. Mendall MA, Patel L, Strachan D, Northfield TC. C reactive protein and its relation to cardiovascular risk factors: A population based cross section study. BMJ. 1996; 312:1061-5.
41. Ridker PM, Cushman M, Stampfer MJ, Tracey RP, Henneken CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy man. N Engl J Med. 1997; 336:973-9.
42. Biasucci LM, Vitelli A, Liuzzo G, Altamura S, Caligiuri G, Monaco C, et al. Elevated levels of interleukin-6 in unstable angina. Circulation. 1996; 94:874-7.
43. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: Is there a link? Lancet. 1997; 350:430-6.
44. Wilhelmsen L, Svärdsudd K, Korsan-Bengtsen K, Larsson BO, Welin L, Tibblin G. Fibrinogen a risk factor for stroke and myocardial infarction. N Engl J Med. 1984; 311:501-5.
45. Haaber AB, Eidmark I, Jensen T, Feldt-Rasmussen B, Strandgaard S. Vascular endothelial cell function and cardiovascular risk factors in patients with chronic renal failure. J Am Soc Nephrol. 1995; 5:1581-4.
46. Bostom AG, Shemin D, Lapane KL, Sutherland P, Nadeau MR, Wilson PWF, et al. Hyperhomocysteinemia, hyperfibrinogenemia, and lipoprotein (a) excess in maintenance dialysis patients: A matched case-control study. Atherosclerosis. 1996; 125:91-101.
47. Koch M, Kutkuhn B, Trenkwalder E, Bach D, Grabensee B, Dieplinger H, et al. Apolipoprotein B, fibrinogen, HDL cholesterol, and apolipoprotein(a) predict coronary heart disease in hemodialysis patients. J Am Soc Nephrol. 1997; 8:1889-98.
48. Bartens W, Nauck M, Schollmeyer P, Wanner C. Elevated lipoprotein(a) and fibrinogen levels increase the cardiovascular risk in continuous ambulatory peritoneal dialysis patients. Perit Dial Int. 1996; 16:27-33.
49. Tomura S, Nakamura Y, Doi M, Ando R, Ida T, Chida Y, et al. Fibrinogen, coagulation factor VII, tissue plasminogen activator inhibitor-1, and lipids as cardiovascular risk factors in chronic hemodialysis and continuous ambulatory peritoneal dialysis patients. Am J Kidney Dis. 1996; 27:848-54.
50. Hajjar KA, Nachman RL. The role of lipoprotein(a) in atherogenesis and thrombosis. Annu Rev Med. 1996; 47:423-42.
51. Wade DP, Clarke JG, Lindahl DG. Control regions of the apolipoprotein(a) gene and members of the related plasminogen family. Proc Natl Acad Sci USA. 1993; 90:1369-73.
52. Maeda S, Abe A, Seishima M, Kakino K, Noma A, Kawade M. Transient changes of serum lipoprotein(a) as an acute phase protein. Atherosclerosis. 1989; 78: 145-50.
53. Kronenberg F, König P, Neyer U, Auinger M, Pribasnig AA, Lang U, et al. Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol. 1995; 6:110-20.
54. Cressman MD, Heyka RJ, Paganini EP, O'Neill J, Skibinski CI, Hoff HF. Circulating lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation. 1992; 86:475-82.
55. Kario K, Matsuo T, Kobayashi H, Matsuo M, Asada R, Koide M. High lipoprotein(a) levels in chronic hemodialysis patients are closely related to the acute phase reaction. Thromb Haemost. 1995; 74:1020-4.
56. Zimmerman J, Herrlinger S, Pruy A, Wanner C. Mechanism of high serum lipoprotein(a) in hemodialysis patients [Abstract]. J Am Soc Nephrol. 1997; 8:260A.
57. Wanner C, Zimmerman J, Quasching T, Galle J. Inflammation, dyslipidemia and vascular risk factors in hemodialysis patients. Kidney Int. 1997; 62(Suppl 62):S53-5.
58. Vallance P, Collier J, Bhagat K. Infection, inflammation, and infarction: Does acute endothelial dysfunction provide a link? Lancet. 1997; 349:1391-2.
59. Docci D, Bilancioni R, Baldrati L, Capponcini C, Turci F, Feletti C. Elevated acute phase reactants in hemodialysis patients. Clin Nephrol. 1990; 34:88-91.
60. Herbelin A, Ngyen A, Zingraff J, Urena P, Deschamp-Latscha B. Influence of uremia and hemodialysis on circulating interleukin-1 and tumor necrosis factor alpha. Kidney Int. 1990; 37:117-25.
61. Haubitz M, Brunkhorst R, Wrenger E, Froese P, Schultze M, Koch K-M. Chronic induction of C-reactive protein by hemodialysis, but not by peritoneal dialysis. Perit Dial Int. 1996; 16:158-62.
62. Bergström J, Heimbürger O, Lindholm B, Qureshi AR. Elevated serum C-reactive protein is a strong predictor of increased mortality and low serum albumin in hemodialysis (HD) patients [Abstract]. J Am Soc Nephrol. 1995; 6:573.
63. Bologna RM, Levine DM, Parker TS, Cheig JS, Serur D, Stenzel KH, et al. High cytokine levels may mediate the high mortality of hemodialysis (HD) patients with low albumin and/or cholesterol (TC) [Abstract]. J Am Soc Nephrol. 1995; 6:573.
64. Han DS, Noh HJ, Shin SH, Lee IH, Kang SW, Choi KH, et al. C-reactive protein: A predictor of mortality in continuous ambulatory peritoneal dialysis (CAPD) patients. J Am Soc Nephrol. 1997; 8:264A.
65. Ikizler TA, Harvell RL, Wingard RL, Shyr V, Hakim RM. C-reactive protein (CRP) is a predictor of hospitalization in chronic hemodialysis (HD) patients [Abstract]. J Am Soc Nephrol. 1997; 8:195A.
66. Bergström J, Lindholm B. Malnutrition, cardiac disease and mortality: an integrated point of view. Am J Kidney Dis. 1998; 32:834-41.